News

Latest News:

mc2_news-image-icon-07

MC2 Therapeutics appoints Christopher S. Billis as Chief Commercial Officer

POSTED: October 25, 2018

Copenhagen, October 25th, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that it has appointed Christopher S. Billis, an experienced healthcare executive within the ...

READ FULL ARTICLE >

MC2 Therapeutics A/S announces topline results showing a favorable safety profile and reduction in corneal staining for MC2-03 in dry eye patients with moderate to severe keratitis

POSTED: October 23, 2018

 

  • Active MC2-03 eye drop treatment resulted in a strong clinical improvement in severe dry eye patients over control arms both on CFS response (p=0.0090) and mean change from Baseline to ...

    READ FULL ARTICLE >

mc2_news-image-icon-04

MC2 Therapeutics A/S announces positive top-line results from Phase 3 clinical trial comparing MC2-01 Cream to Taclonex® in adults with psoriasis

POSTED: August 21, 2018

MC2-01 Cream demonstrates statistically significant superiority in both treatment success and patient reported treatment convenience compared to Taclonex® Topical Suspension. Both primary and secondary endpoints were met and a submission ...

READ FULL ARTICLE >

mc2_news-image-icon-07

MC2 Therapeutics A/S announces completion of recruitment in US Phase 3 trial in Psoriasis Vulgaris

POSTED: April 2, 2018

  • Topline results are expected in Q3 2018

Copenhagen, April 2nd, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that the patient enrollment for the Phase ...

READ FULL ARTICLE >

Upcoming Events:

There are no upcoming events at the moment.

READ MORE >

© mc2 therapeutics 2020